You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NKG2D-ACE2 CAR-NK

Showing 1 - 25 of 5,495
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Trial in Chongqing (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

Recruiting
  • COVID-19
  • NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
  • Chongqing, China
    Chongqing Public Health Medical Center
Nov 16, 2020

Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • Ovarian Cancer
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Mar 26, 2023

AML Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • AML
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 17, 2023

Refractory Metastatic Colorectal Cancer Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
Jan 16, 2022

Safety and Efficacy Trial in Sanhe (CAR-NK cells)

Recruiting
  • Safety and Efficacy
  • CAR-NK cells
  • Sanhe, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Feb 9, 2022

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)

Not yet recruiting
  • Gastric Cancer
  • +2 more
  • KD-496
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 15, 2023

Refractory Metastatic Colorectal Cancer Trial in Guangzhou (CAR-T infusion)

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • CAR-T infusion
  • Guangzhou, Guangdong, China
    The Third Affiliated Hospital of Guangzhou Medical University
Feb 9, 2022

Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)

Recruiting
  • Gastric Cancer
  • +2 more
  • KD-496
  • Beijing, China
    Chinese PLA General Hospital
Oct 13, 2022

Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)

Not yet recruiting
  • Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma Trial in Houston (TROP2-CAR-NK, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Pancreatic Cancer
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 27, 2023

CRC, Solid Tumor Trial in Beijing (KD-025)

Recruiting
  • CRC
  • Solid Tumor
  • KD-025
  • Beijing, Beijing, China
    Chinese PLA General Hospital
May 16, 2022

Advanced Solid Tumors Trial in Hangzhou (Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))

Recruiting
  • Advanced Solid Tumors
  • Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
  • Hangzhou, China
    First affiliated hospital, School of Medicine, Zhejiang Universi
Aug 3, 2023

Acute Myeloid Leukemia Trial (NK cells, Talazoparib 1 MG [Talzenna])

Not yet recruiting
  • Acute Myeloid Leukemia
  • NK cells
  • Talazoparib 1 MG [Talzenna]
  • (no location specified)
Jan 9, 2023

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

Recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • NKG2D-based CAR T-cells
  • Jiujiang, Jiangxi, China
    Xunyang Changchun Shihua Hospital
Nov 20, 2021

B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • CB dualCAR-NK19/70
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022

Cancer, Malignancy, Refractory Cancer Trial in Singapore (Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted ?d T

Not yet recruiting
  • Cancer
  • +3 more
  • Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
  • Singapore, Singapore
    National University Hospital
Mar 20, 2022

B-cell Non Hodgkin Lymphoma Trial in Hanzhou (anti-CD19 CAR-NK)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • anti-CD19 CAR-NK
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jul 21, 2022

Advanced Solid Tumor Trial in Shanghai (IMC008)

Recruiting
  • Advanced Solid Tumor
  • Shanghai, Shanghai, China
    Shanghai Changhai Hospital
Apr 19, 2023

Recurrent Glioblastoma Trial (NKG2D CAR-T)

Not yet recruiting
  • Recurrent Glioblastoma
  • NKG2D CAR-T
  • (no location specified)
Jan 16, 2021

NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)

Not yet recruiting
  • NHL, Relapsed, Adult
  • +3 more
  • KUR-502
  • (no location specified)
Aug 2, 2022

Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)

Not yet recruiting
  • Large B-cell Lymphoma
  • B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2023

Acute Myeloid Leukemia Trial in Hangzhou (NKG2D CAR T-cells)

Not yet recruiting
  • Acute Myeloid Leukemia
  • NKG2D CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
Dec 5, 2020

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

Withdrawn
  • Hepatocellular Carcinoma
  • +3 more
  • NKG2D-based CAR T-cells
  • Jiujiang, Jiangxi, China
    Affiliated hospital of jiujiang university
Oct 18, 2020

Colon Cancer, Resected Stage Trial in Houston (Cetuximab, CB-NK-TGF-βR2-/NR3C1, Fludarabine phosphate)

Recruiting
  • Colon Cancer
  • Resected Stage
  • Houston, Texas
    M D Anderson Cancer Center
Jul 23, 2022